Nov 29, 2022 / 08:05PM GMT
Umer Raffat - Evercore ISI Institutional Equities, Research Division - Senior MD & Senior Analyst of Equity Research
Thank you guys for joining us. It's a pleasure to have Amylyx management join us. There's a lot to discuss. And I'm looking forward to the discussion, but let me first turn it over to you guys, if you want to kick it off.
Unidentified Company Representative -
Yes. Very happy to -- well, first of all, thanks so much for having us and really excited to get to share with you all. So Justin, Josh, Jim, so the management team here at Amylyx. Amylyx is focused in ending the suffering caused by neurodegenerative diseases. And I think particularly, things are focused right now around RELYVRIO in the U.S., ALBRIOZA in Canada, which is our newly approved treatment for ALS. So this is an exciting time for us. The FDA approval is just September 29. And our team is hard at work, focused on making sure that we deliver for a community that really needs us. The main things right now are everything you would expect at launch, although it's just the early weeks now.
Amylyx Pharmaceuticals Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Nov 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers